Pfizer, Inc. company logo

# 1st Gen Model Pfizer, Inc. Pharmaceutical preparations

  • $34.04Last close price
    at 26-jun-2017
  • Subscribe >>
  • 62.96% successful of 54 deals

PFE

Model's trade recommendations -1.30% Return for period

-2.24% Annual return

$203.92B Market Cap

β 1.02  

PFE

Model (following trade recommendations)

PFE

Underlying stock

S&P 500

Index
Return for period -1.30%
5.94%
1.78%
52wk return -3.84%
0.71%
16.82%
52wk Range
29.89—37.31
2000.54—2399.63
Sortino ratio -0.48
Sharpe ratio -0.41
Norm. RMSE 0.35%
Downside risk 5.06%
Volatility 5.85%
  • 1.28 (3.75%) Div (Yield)
  • BUY Analysts consensus recommendation

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Pfizer, Inc. (PFE) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 10, 2014.

Market data for PFE model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 5964M
P/E 14.18
Shares Outstanding 5968M
% Held by Insiders 0.06%
% Held by Institutions 69.97%
EPS (last reported FY) $2.40
EPS (last reported Q) $0.69
EPS, estimated (last reported Q) $0.67
Total revenues $53 B
Net income $7 B